Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06973577 · ClinicalTrials.gov registry record · Phase 3
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
A Phase 3 study of Anxiety and ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 308
- Enrollment target
- 20
- Study locations
NCT06973577 is a Phase 3 study of Anxiety and ADHD that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 308 participants, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT06973577, a Phase 3 study of Anxiety and ADHD, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 308 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Centanafadine
Study Locations (20)
California
- Clinical Research Site #052 - Leading Edge Research LA, LLC - Encino
- Clinical Research Center #008 - Long Beach Clinical Trial Services Inc. - Long Beach
- Clinical Research Site #008 - Long Beach Clinical Trial Services Inc. - Long Beach
- Clinical Research Site #011 - NRC Research Institute - Orange
- Clinical Research Center #042 - Anderson Clinical Research - Redlands
- Clinical Research Site #037 - Cenexel CIT IE (Clinical Innovations Inc) - Riverside
- Clinical Research Site #039 - California Neuroscience Research, LLC - Sherman Oaks
- Clinical Research Site #038 - Sunwise Clinical Research - Walnut Creek
Florida
- Clinical Research Center #035 - Sarkis Clinical Trials - Gainesville
- Clinical Research Site #005 - Clinical Neuroscience Solutions, Inc. - Jacksonville
- Clinical Research Site #046 - ARSN-Largo CRU - Largo
- Clinical Research Site #010 - Meridien Research/Accel Clinical - Maitland
- Clinical Research Site #015 - Medical Research Group of Central Florida - Orange City
- Clinical Research Site #006 - CNS Healthcare Orlando - Orlando
- Clinical Research Site #019 - Segal Trials Innovatice Clinical Research, Inc. - Tamarac
Arkansas
- Clinical Research Center #033 - Woodland International Research Group - Little Rock
- Clinical Research Center #048 - Woodland Research Northwest - Rogers
Alabama
- Clinical Research Site #017 - Harmonex Neuroscience Research - Dothan
Colorado
- Clinical Research Site #030 - MCB Clinical Research Centers - Colorado Springs
Connecticut
- Clinical Research Site #045 - Research Center for Clinical Studies - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2027-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06973577
The ClinicalTrials.gov registry entry for NCT06973577 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 364 other Anxiety trials with a reported enrollment target (30% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06973577 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06973577 about?
NCT06973577 is a clinical study titled "P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety". Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults ages with ADHD and comorbid anxiety
What is the current status of trial NCT06973577?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 308 participants. The study started on 2025-03-26. Estimated completion is 2027-10-04.
What conditions does trial NCT06973577 study?
This clinical trial studies the following conditions: Anxiety, ADHD, Social Anxiety Disorder, Generalized Anxiety.
What interventions are being tested in trial NCT06973577?
The interventions under investigation include: Placebo (OTHER), Centanafadine (DRUG).
Who is sponsoring clinical trial NCT06973577?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06973577 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
REmotely-delivered Supportive Programs for Improving Surgical Pain and disTrEss
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
COMPLETED · Phase 3
-
Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth
COMPLETED · Phase 3
-
A Study Comparing Two Treatments for Child With Anxiety
COMPLETED · Phase 3
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.